These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23456745)

  • 21. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Ujjani C; Ramzi P; Gehan E; Wang H; Wang Y; Cheson BD
    Leuk Lymphoma; 2015 Apr; 56(4):915-20. PubMed ID: 24925211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use.
    Gravanis I; Ersbøll J; Skovlund E; Abadie E; Marty M; Pignatti F
    Oncologist; 2010; 15(12):1335-43. PubMed ID: 21156732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Costa LJ; Fanning SR; Stephenson J; Afrin LB; Kistner-Griffin E; Bentz TA; Stuart RK
    Leuk Lymphoma; 2015 Mar; 56(3):645-9. PubMed ID: 25130476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ofatumumab for the treatment of chronic lymphocytic leukemia.
    Grosicki S
    Expert Rev Hematol; 2015 Jun; 8(3):265-72. PubMed ID: 25882470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
    Barth MJ; Czuczman MS
    Future Oncol; 2013 Dec; 9(12):1829-39. PubMed ID: 24295413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ofatumumab in the treatment of chronic lymphocytic leukemia.
    Tsimberidou AM
    Drugs Today (Barc); 2010 Jul; 46(7):451-61. PubMed ID: 20683500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ofatumumab.
    Sanford M; McCormack PL
    Drugs; 2010 May; 70(8):1013-9. PubMed ID: 20481657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
    Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
    Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
    Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
    Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
    Reagan JL; Castillo JJ
    Future Oncol; 2014 May; 10(7):1147-55. PubMed ID: 24947256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
    Coiffier B; Radford J; Bosly A; Martinelli G; Verhoef G; Barca G; Davies A; Decaudin D; Gallop-Evans E; Padmanabhan-Iyer S; Van Eygen K; Wu KL; Gupta IV; Lin TS; Goldstein N; Jewell RC; Winter P; Lisby S;
    Br J Haematol; 2013 Nov; 163(3):334-42. PubMed ID: 24032456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
    Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
    Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
    Österborg A; Wierda WG; Mayer J; Hess G; Hillmen P; Schetelig J; Schuh A; Smolej L; Beck C; Dreyfus B; Hellman A; Kozlowski P; Pfreundschuh M; Rizzi R; Spacek M; Phillips JL; Gupta IV; Williams V; Jewell RC; Nebot N; Lisby S; Dyer MJ
    Br J Haematol; 2015 Jul; 170(1):40-9. PubMed ID: 25825041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
    Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
    Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program.
    Dupuis J; Brice P; François S; Ysebaert L; de Guibert S; Levy V; Leprêtre S; Choquet S; Dilhuydy MS; Fornecker L; Morel V; Tempescul A
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):e43-6. PubMed ID: 25193089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.
    Schweighofer CD; Tuchscherer A; Sperka S; Meyer T; Rattel B; Stein S; Ismail S; Elter T; Staib P; Reiser M; Hallek M
    Cancer Immunol Immunother; 2012 Dec; 61(12):2367-73. PubMed ID: 23090290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.
    Patton WN; Lindeman R; Butler AC; Kipps TJ; Jewell RC; Laubscher KH; Zhou YY; Lewis E; Sedoti D; Witman P; Fang L; Chan G
    Leuk Lymphoma; 2015; 56(10):2819-25. PubMed ID: 25721750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
    Jaglowski SM; Jones JA; Nagar V; Flynn JM; Andritsos LA; Maddocks KJ; Woyach JA; Blum KA; Grever MR; Smucker K; Ruppert AS; Heerema NA; Lozanski G; Stefanos M; Munneke B; West JS; Neuenburg JK; James DF; Hall N; Johnson AJ; Byrd JC
    Blood; 2015 Aug; 126(7):842-50. PubMed ID: 26116658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
    Howard DR; Munir T; Hockaday A; Rawstron AC; Collett L; Oughton JB; Allsup D; Bloor A; Phillips D; Hillmen P
    Trials; 2016 Sep; 17(1):456. PubMed ID: 27645620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.